Myfortic (Mycophenolic Acid)

Mycophenolic Acid selectively inhibits the enzyme inosine monophosphate dehydrogenase (IMPDH), which is essential for the synthesis of guanosine nucleotides in lymphocytes. By blocking this pathway, the drug reduces the production of DNA and RNA in T‑ and B‑cells, suppressing their proliferation and activity. This targeted immunosuppression helps to prevent the immune system from attacking a newly transplanted organ.

The specific dose of Myfortic is determined by the prescribing physician based on the patient’s transplant type, body weight, renal function, and concomitant medications. Dosing is individualized and may be adjusted over time to achieve the desired immunosuppressive effect while minimizing adverse reactions. Patients should follow the exact regimen provided by their healthcare professional and not alter the dose on their own.

The safety of Myfortic (mycophenolate) during pregnancy and lactation is not well established, and it is generally classified as contraindicated for use in pregnant women because of potential teratogenic effects. Women of child‑bearing potential should use effective contraception while taking the drug and for a defined period after discontinuation. Breastfeeding is also discouraged, as the medication can be excreted in milk and affect the infant.

To place an order for Myfortic, submit an enquiry on the product page at gnhindia.com, specifying the required quantity and providing institutional or trade credentials. GNH India works with hospitals, pharmacies, and procurement teams worldwide, and will respond with pricing, availability, shipping details (including any temperature‑controlled requirements), and the necessary import documentation to complete the purchase.

Myfortic (mycophenolate sodium) is an antimetabolite that offers a more favorable gastrointestinal tolerability profile compared with mycophenolate mofetil, its counterpart, due to its delayed‑release formulation. Both agents share the same mechanism of IMPDH inhibition, but Myfortic may be preferred in patients who experience significant nausea or vomiting with other formulations. Choice of therapy depends on individual patient response, side‑effect tolerance, and physician preference.

Myfortic tablets should be stored at ambient temperature, below 25 °C, in their original packaging to protect them from moisture and light. Keep the container tightly closed and avoid storing the medication in bathrooms or near heat sources. Do not freeze the tablets, and discard any product that appears discoloured or damaged.

Myfortic is taken orally, usually as whole tablets, with or without food as directed by the prescribing clinician. The tablets should be swallowed whole with a glass of water and not chewed, crushed, or split unless specifically instructed. Consistent timing each day helps maintain stable blood levels, and patients should follow the dosing schedule provided by their transplant team.

The most serious risks of Myfortic include severe infections due to immunosuppression, hematologic abnormalities such as leukopenia or anemia, and an increased risk of certain malignancies, including lymphomas and skin cancers. Liver injury and progressive multifocal leukoencephalopathy (PML) are rare but potentially fatal complications. Patients should be monitored regularly for signs of infection, blood count changes, and any new skin lesions.

Myfortic is contraindicated in individuals with known hypersensitivity to mycophenolate sodium or any of its excipients. It should also be avoided in patients with active, uncontrolled infections, severe hepatic impairment, or those receiving live vaccines. Pregnant women and breastfeeding mothers are advised not to use the drug due to potential fetal and infant harm. Clinical judgment is required to assess suitability for each patient.